Related references
Note: Only part of the references are listed.Review article: Latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-Risks, screening, diagnosis and management
Sasha R. Fehily et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region
Peeyush Kumar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study
Abel B. Quaresma et al.
LANCET REGIONAL HEALTH-AMERICAS (2022)
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Myeong Geun Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2022)
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Geert R. D'Haens et al.
GUT (2021)
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T. Kucharzik et al.
JOURNAL OF CROHNS & COLITIS (2021)
EPIDEMIOLOGICAL PROFILE AND CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASES IN A BRAZILIAN REFERRAL CENTER
Luiza Maria Pilau FUCILINI et al.
Arquivos de Gastroenterologia (2021)
Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review
Paulo Gustavo Kotze et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
Saurabh Kedia et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Safety considerations with biologics and new inflammatory bowel disease therapies
Natalia S. F. Queiroz et al.
CURRENT OPINION IN GASTROENTEROLOGY (2020)
Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America
Flora Maria Lorenzo Fortes et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
Christian Maaser et al.
JOURNAL OF CROHNS & COLITIS (2019)
The prevalence and phenotype in Brazilian patients with inflammatory bowel disease
Adalberta Lima Martins et al.
BMC GASTROENTEROLOGY (2018)
A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases
Choon Kin Lee et al.
JOURNAL OF CROHNS & COLITIS (2018)
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Carlos Taxonera et al.
JOURNAL OF CROHNS & COLITIS (2018)
Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
Siew C. Ng et al.
INFLAMMATORY BOWEL DISEASES (2018)
COMPARISON OF RATES OF ACTIVE TUBERCULOSIS INFECTION IN THE PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS FOR ANTI-IL12/23 AND ANTI-TNFS
Edward V. Loftus et al.
GASTROENTEROLOGY (2017)
Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil
Claudia Leiko Yonekura et al.
Revista Brasileira De Reumatologia (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment
D. Carpio et al.
JOURNAL OF CROHNS & COLITIS (2016)
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort
Yael Abitbol et al.
JOURNAL OF CROHNS & COLITIS (2016)
Tuberculosis
Madhukar Pai et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Biologic Agents and Tuberculosis
Claudia C. Dobler
MICROBIOLOGY SPECTRUM (2016)
The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
Ja Min Byun et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil
Jose Miguel Luz Parente et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials
Roberto Lorenzetti et al.
ANNALS OF MEDICINE (2014)
Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: Still room for improvement
Míriam Mañosa et al.
Journal of Crohns & Colitis (2013)
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening
Aranzazu Jauregui-Amezaga et al.
JOURNAL OF CROHNS & COLITIS (2013)
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors
P. Papay et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Multiscale Computational Modeling Reveals a Critical Role for TNF-α Receptor 1 Dynamics in Tuberculosis Granuloma Formation
Mohammad Fallahi-Sichani et al.
JOURNAL OF IMMUNOLOGY (2011)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)